Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

November 30, 2020

Study Completion Date

February 1, 2022

Conditions
Atrial FibrillationPeriodontal DiseaseHemorrhage
Interventions
DRUG

Rivaroxaban

Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.

DRUG

Dabigatran and Apixaban

Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.

DRUG

Warfarin

The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0

Trial Locations (1)

05403000

Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo

All Listed Sponsors
lead

University of Sao Paulo General Hospital

OTHER

NCT03181386 - Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants | Biotech Hunter | Biotech Hunter